Abstract

BackgroundTwo JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents has been of interest since the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
Pablo A Olivera ... Laurent Peyrin-Biroulet
Gastroenterology | VOL. 158
Pablo A Olivera, et. al.Pablo A Olivera ... Laurent Peyrin-Biroulet
09 Jan 2020
Tofacitinib: Janus Bifrons in Ulcerative Colitis Treatment
Laurent Peyrin–Biroulet ... Silvio Danese
Gastroenterology | VOL. 144
Laurent Peyrin–Biroulet, et. al.Laurent Peyrin–Biroulet ... Silvio Danese
23 Mar 2013
Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa.
N Singh ... D Grand
Clinical and experimental dermatology | VOL. 45
N Singh, et. al.N Singh ... D Grand
26 May 2020
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.
Rieke Alten ... Ingrid Delaet
Arthritis & rheumatology (Hoboken, N.J.) | VOL. 66
Rieke Alten, et. al.Rieke Alten ... Ingrid Delaet
28 Jul 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers